

AN ORDINANCE **9 8588**

AUTHORIZING THE ACCEPTANCE OF UP TO \$50,868.00 FROM SMITHKLINE BEECHAM CORPORATION, D/B/A GLAXOSMITHKLINE (GSK) FOR THE SAN ANTONIO METROPOLITAN HEALTH DISTRICT TO PARTICIPATE DURING THE PERIOD JANUARY 1, 2004 THROUGH DECEMBER 31, 2005 IN A FOLLOW-UP VACCINE STUDY FOR THE PREVENTION OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION IN WOMEN; AUTHORIZING THE EXECUTION OF THE CLINICAL STUDY AGREEMENT WITH GSK; ESTABLISHING A FUND; ADOPTING THE PROJECT BUDGET, APPROVING THE PERSONNEL COMPLEMENT; AND APPROVING PAYMENTS FOR CONTRACTUAL SERVICES.

* * * * *

WHEREAS, GlaxoSmithKline (GSK), one of the world's leading pharmaceutical and healthcare companies, has offered a Clinical Study Agreement to the San Antonio Metropolitan Health District (SAMHD) during the period January 1, 2004 through December 31, 2005; and

WHEREAS, this agreement will provide up to \$50,868.00 for the SAMHD to participate in a follow-up vaccine study for the prevention of human papillomavirus (HPV) cervical infection in adolescent and young adult women; and

WHEREAS, the SAMHD desires to participate in this follow-up study and to provide participants with vaccines free of charge; and

WHEREAS, the SAMHD desires to reimburse the enrollees in the study for expenses that may be incurred through their participation in this project; and

WHEREAS, it is now necessary to authorize the acceptance and execution of this agreement with GSK, establish a fund, adopt the project budget, approve the personnel complement and approve the payment of stipends of up to \$350.00 to each enrollee in the study; **NOW THEREFORE:**

BE IT ORDAINED BY THE CITY COUNCIL OF THE CITY OF SAN ANTONIO:

SECTION 1. The City Manager, or her designee, is hereby authorized to accept and execute Clinical Study Agreement Protocol 580299/007 with GlaxoSmithKline during the period January 1, 2004 through December 31, 2005, which will provide up to \$50,868.00 for the San Antonio Metropolitan Health District to participate in a follow-up vaccine study for the prevention of human papillomavirus (HPV) cervical infection in adolescent and young adult women. A copy of this agreement, in substantially correct form, is set out as Attachment II and incorporated herein for all purposes.

SECTION 2. Fund 26-012257 entitled "Human Papillomavirus (HPV) Study Project" is designated for use in accounting for this project.

SECTION 3. The sum of \$50,868.00 is hereby appropriated in the above-designated fund for the Human Papillomavirus (HPV) Study Project, and the budget attached hereto and incorporated herein as Attachment I is approved and adopted for entry on the City's books.

SECTION 4. The two (2) personnel positions set out in Attachment I are hereby authorized for the Human Papillomavirus (HPV) Study Project.


SECTION 5. Payments in an aggregate amount not to exceed \$6,300.00 are authorized to be paid out as stipends of up to \$350.00 to each participant in the vaccine study. Payments will be made from Fund 26-012257, Activity Code 36-07-17, Index No. 484436.


SECTION 6. The Director of Finance, may, subject to concurrence by the City Manager or the City Manager's designee, correct allocation to specific index codes and fund numbers as necessary to carry out the purpose of this ordinance.


SECTION 7. Should the agreement offered be in an amount other than that budgeted for, or should the agreement contain terms and conditions different than those currently existing, acceptance of the agreement, budget and corresponding personnel complement will be subject to subsequent City Council ordinance.

SECTION 8. This ordinance shall be effective on and after the tenth day after passage hereof.

PASSED AND APPROVED this 18th day of December, 2003.


M A Y O R
EDWARD D. GARZA

ATTEST: 
City Clerk

APPROVED AS TO FORM: 
City Attorney